Comparison of the Efficacy and Safety of Continuous and Single-Dose Intravesical Epirubicin Instillation
Status:
Not yet recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
In this study, the local and systemic side effects, tumor recurrens and progression rates of
single or continuous epirubicin instillation during the early postoperative period were
investigated in low and intermediate risk non-muscle-invasive bladder cancer.